Global Trends in Medication-Based Addiction Treatment show a major shift in how alcohol and opioid use disorders are being treated around the world.
Addiction treatment is increasingly moving away from the idea that every patient should follow the same pathway.
Instead, health systems are expanding combinations of:
- methadone;
- buprenorphine;
- naltrexone;
- acamprosate;
- disulfiram;
- long-acting medication formulations;
- behavioral treatment;
- peer and recovery support;
- telehealth and flexible treatment delivery.
At the same time, one of the world’s largest addiction-treatment problems remains unresolved:
The 2026 United Nations World Drug Report continues to show extremely low global treatment coverage, with major differences between countries, regions, substances and treatment systems.
The important global story is therefore not simply the invention of new medicines.
It is also about making proven treatments easier to access, easier to continue and easier to fit into normal life.
Medication Is Moving From a Specialist Exception Toward a Core Part of Addiction Healthcare
The strongest international direction is toward evidence-based medication combined with individualized psychosocial care, harm reduction, medical treatment and long-term recovery support.
These figures come from different surveillance systems and should not be compared as though their populations and methods were identical. They illustrate treatment-access patterns rather than direct country-to-country performance rankings.
How medication-based addiction treatment is changing globally, why methadone and buprenorphine remain central to opioid treatment, where naltrexone fits, why long-acting medicines are expanding, how alcohol medications are gaining international recognition, what is changing in the United States and Europe, and what these trends may mean for an individual treatment decision.
Prepared for medical review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry
Review status: Pending clinical approval
View Dr Fergus Law’s Clinical & Scientific Profile →What Is Medication-Based Addiction Treatment?
Medication-based addiction treatment uses medicines to address specific biological components of a substance use disorder.
Depending on the medication, treatment may:
- reduce withdrawal;
- reduce craving;
- stabilize opioid receptors;
- block opioid effects;
- reduce the rewarding effects of alcohol;
- help maintain abstinence;
- reduce heavy drinking;
- support treatment retention.
Different countries use different terminology.
Many U.S. organizations increasingly use MOUD or MAUD because the medication is itself an evidence-based treatment — not merely an “assistant” to another form of treatment.
Most People With Drug Use Disorders Still Do Not Receive Treatment
The UNODC World Drug Report 2026 reports that global progress toward adequate treatment coverage remains limited.
Its new estimates indicate that at minimum about 8.2% of people with substance use disorders receive treatment.
Coverage varies considerably by:
- country;
- region;
- gender;
- urban versus rural location;
- primary substance;
- healthcare resources;
- legal and regulatory structure.
UNODC’s available country data also show major differences in the types of treatment delivered.
Pharmacological interventions are especially prominent in Europe and Asia, while the Americas report a larger proportion of psychosocial, behavioral and rehabilitation interventions.
Treatment definitions, reporting systems and data quality differ substantially between countries. Global statistics should therefore be interpreted as broad public-health indicators rather than precise comparisons between individual treatment systems.
Trend: Addiction Treatment Is Moving Away From a Single-Model Approach
Historically, medication was sometimes treated as incompatible with “real recovery.”
Modern evidence-based treatment increasingly rejects that distinction.
The precise combination differs from person to person.
Opioid Agonist Treatment Remains the Global Foundation of OUD Medication Treatment
WHO continues to identify opioid agonist maintenance treatment with medicines such as methadone and buprenorphine as the preferred pharmacological intervention for most people with opioid dependence.
WHO cites evidence across outcomes including:
Methadone
A long-established OUD treatment used internationally.
Buprenorphine
Available in oral/transmucosal and increasingly long-acting formulations.
Naltrexone
An abstinence-oriented antagonist option requiring opioid-free preparation before treatment.
Naltrexone Is an Evidence-Based Option — But It Is Not Pharmacologically Equivalent to Methadone or Buprenorphine
Methadone and buprenorphine suppress opioid withdrawal and craving through opioid-receptor activity. Naltrexone blocks opioid receptors and requires successful withdrawal before initiation.
Trend: Long-Acting Formulations Are Expanding
One of the clearest medication-development trends is movement from daily dosing toward formulations that last longer.
Greater patient control but repeated adherence decisions.
Available in the U.S. through weekly Brixadi formulations.
Monthly extended-release options can reduce dosing frequency.
Some countries and research programs use or study longer-lasting formulations.
In 2023, the FDA approved Brixadi extended-release buprenorphine in weekly and monthly formulations.
Europe is also using newer prolonged-release buprenorphine injections, and EUDA reports use of newer buprenorphine preparations in several European countries.
Less frequent dosing may reduce missed doses, medication diversion, repeated clinic attendance and the opportunity to stop medication impulsively. It may also make treatment easier for some people living far from specialist services.
A longer-acting product still needs evidence for safety and effectiveness, appropriate patient selection and a plan for adverse effects or changing treatment needs.
Trend: Medication Treatment Is Becoming More Flexible
Another important international trend is reducing unnecessary barriers to staying in treatment.
More Treatment Outside Specialist Centers
Some medication treatment can increasingly be integrated into ordinary healthcare.
Remote Assessment and Follow-Up
Regulatory changes in some countries allow parts of treatment to occur remotely.
Less Frequent Clinic Attendance
Carefully selected patients may receive more flexible medication arrangements.
Fewer Administration Visits
Weekly or monthly formulations can reduce logistical barriers.
Treatment Reaches Underserved Areas
Mobile treatment units can reduce transportation and geographic barriers.
More Patient Choice
Treatment increasingly considers patient preferences alongside clinical risk.
Europe: High Use of Opioid Agonist Treatment — but Uneven Coverage
EUDA estimates that approximately 505,000 people received opioid agonist treatment in EU Member States in 2024.
That represented approximately 60% of the estimated 855,000 high-risk opioid users.
These percentages describe opioid agonist treatment clients included in EUDA reporting.
EUDA also reports that treatment provision remains inadequate in some countries, demonstrating that being within a high-income region does not guarantee equal medication access.
Newer buprenorphine preparations — including prolonged-release injections and subcutaneous implants — are being used in a growing number of European settings.
U.S. Trend: Lower Regulatory Barriers, but Medication Remains Underused
Several important U.S. policy changes have attempted to make OUD medication easier to obtain.
The X-Waiver Was Eliminated
The separate federal DATA waiver previously required for prescribing buprenorphine for OUD was removed.
Methadone Take-Home Rules Became More Flexible
Revised federal rules permit more individualized take-home decisions based on clinical judgment.
Telehealth Has a Larger Role
Under specified circumstances, telehealth can be used for parts of opioid-treatment-program admission and assessment.
Long-Acting Buprenorphine Options Expanded
Weekly and monthly extended-release buprenorphine options are now available.
SAMHSA reported that only 15.7% of people with past-year OUD received medications for OUD in 2025.
Regulatory change therefore does not automatically eliminate barriers such as stigma, limited providers, cost, geography, transportation or reluctance to seek treatment.
Trend: Medication for Alcohol Use Disorder Is Gaining Greater Global Recognition
Medication discussions often focus on opioids, but pharmacological treatment is also established for alcohol use disorder.
In 2023, WHO added naltrexone and acamprosate to its Model List of Essential Medicines for treatment of alcohol use disorders.
This was an important international development because inclusion on the WHO list can support countries seeking to improve procurement, affordability and integration into health systems.
Naltrexone
Can reduce alcohol reward, craving and heavy drinking in some patients.
Acamprosate
Helps some patients maintain abstinence after alcohol withdrawal.
Disulfiram
Produces an unpleasant reaction if alcohol is consumed and can support selected motivated patients.
SAMHSA reported that only 2.6% of Americans with past-year AUD received medication for AUD in 2025.
The next major advance in alcohol treatment may depend as much on using existing medications more consistently as on discovering completely new medicines.
Cocaine and Methamphetamine Highlight the Medication Gap
Medication-based treatment has advanced considerably for opioid and alcohol use disorders.
The situation is different for stimulant use disorder.
There is currently no FDA-approved medication specifically for stimulant use disorder in the United States.
Behavioral interventions therefore remain central.
Contingency Management Remains a Leading Evidence-Based Treatment for Stimulant Use Disorder
Research continues into pharmacological approaches, but promising research findings should not be presented as though an approved medication already exists.
A naltrexone implant should not be presented as an established medication treatment for cocaine or methamphetamine use disorder. If stimulant use coexists with an opioid or alcohol use disorder, naltrexone may have a separate indication for that co-occurring condition.
Trend: Shared Decision-Making Is Replacing “One Treatment Fits Everyone”
Modern medication treatment increasingly considers both clinical evidence and patient preferences.
For OUD, this means patients should generally receive a meaningful discussion of methadone, buprenorphine and naltrexone rather than being offered only the medication a particular clinic happens to favor.
Trend: Treatment Systems Are Paying More Attention to Continuity
WHO’s 2025 guidance describes opioid agonist maintenance treatment as an essential health service that should remain available even during crises and service disruptions.
This reflects a broader shift:
Interruptions can occur because of:
Modern systems are increasingly being judged not only on whether they can start treatment, but whether they can keep patients connected to it.
See How the Main U.S. Opioid Medications Differ
The U.S. National Institute on Drug Abuse provides a clear educational demonstration of the major medication categories used in opioid addiction and overdose treatment.
Medications for Opioid Use Disorder
The video explains naloxone for overdose reversal, medication for opioid withdrawal, buprenorphine, methadone and naltrexone.
Where Naltrexone Fits in Global Medication-Based Addiction Treatment
Naltrexone occupies a different position from methadone and buprenorphine.
It is an opioid receptor antagonist rather than an opioid agonist.
Opioid Use Disorder
Naltrexone can support prevention of return to opioid dependence after the patient has completed appropriate opioid withdrawal.
In the United States, extended-release injectable naltrexone is an FDA-approved OUD medication.
A major clinical difference is that naltrexone cannot normally be started while a person remains physically dependent on opioids.
Starting too soon can precipitate severe withdrawal.
Alcohol Use Disorder
Naltrexone also has an established role in alcohol use disorder.
WHO’s inclusion of naltrexone on the Model List of Essential Medicines for AUD reflects its international importance.
Methadone / Buprenorphine
Stabilize opioid receptor activity and reduce withdrawal and craving.
Naltrexone
Blocks opioid receptors after successful opioid withdrawal.
Naltrexone Implants: An International but Non-Uniform Treatment Category
Sustained-release naltrexone implants have been developed and used or studied in some countries to maintain naltrexone exposure for longer than oral medication.
Their regulatory status is not internationally uniform.
Naltrexone implants are not FDA-approved formulations in the United States. The FDA-approved long-acting naltrexone formulation for OUD is extended-release intramuscular naltrexone.
A 2025 Cochrane review examined sustained-release naltrexone products, including injectable and implantable formulations.
The review found potential advantages over oral naltrexone or treatment as usual for some outcomes, but substantial uncertainty remains for several comparisons.
Evidence comparing sustained-release naltrexone with opioid agonist treatments such as methadone or buprenorphine is less certain.
Long Duration Is a Practical Feature — Not Proof That One Medication Is Universally Superior
Medication selection should consider evidence, the patient’s goals, opioid-free preparation, adherence, treatment history, safety and availability of other proven options.
Six Trends Likely to Shape the Next Generation of Addiction Treatment
More Treatment in General Healthcare
Addiction medication becoming less isolated from primary and general medical care.
More Long-Acting Formulations
Weekly, monthly and potentially longer-duration delivery systems.
Fewer Unnecessary Access Barriers
Telehealth, mobile treatment and more flexible follow-up models.
Better Global Medicine Supply
WHO’s 2026 prequalification initiative aims to expand access to quality-assured methadone, buprenorphine and naloxone.
More Individualized Treatment
Medication choice increasingly based on patient needs rather than one clinic philosophy.
Greater Integration With Recovery Support
Medication increasingly treated as part of a broader strategy addressing mental health, behavior and social recovery.
How Should a Patient Think About Medication Options?
Population trends can show what treatment systems are doing.
They cannot determine which medication is right for one person.
Long-Acting Naltrexone as One Treatment Pathway
DeBinge uses a long-acting naltrexone approach for clinically appropriate patients alongside professional counseling and ongoing recovery support.
The model may be particularly relevant to somebody who:
- has an opioid or alcohol use disorder appropriate for naltrexone;
- prefers an antagonist-based treatment approach;
- can complete required opioid-free preparation where applicable;
- has struggled with daily medication adherence;
- wants a longer period of medication coverage;
- is willing to participate in continuing counseling and recovery planning.
A patient with opioid use disorder should receive an informed discussion of established alternatives, including methadone and buprenorphine, because these treatments have particularly strong evidence for retention and mortality reduction.
Long-Acting Naltrexone Plus One Year of Professional Counseling
The objective is not simply to place an implant.
The medication period can be used to work on triggers, behavior, relationships, routine and a sustainable long-term recovery plan.
Could Medication-Based Treatment Strengthen Your Recovery Plan?
This assessment does not tell you which prescription to take.
It identifies questions that may deserve a professional medication review and produces different next-step roadmaps based on your answers.
It can identify issues involving:
- withdrawal;
- cravings;
- repeated relapse;
- opioid-overdose risk;
- current medication effectiveness;
- difficulty taking daily medication;
- access and transportation;
- opioid-free preparation;
- alcohol medication options;
- long-acting treatment preferences.
20 Questions • About 5 Minutes
Answer according to your current situation.
This educational tool is not a diagnosis and cannot prescribe, recommend or rule out an individual medication.
Medication Planning Can Wait — the Emergency Cannot
If opioid overdose is suspected, give naloxone if available and call 911.
Severe alcohol withdrawal, seizures, major confusion, hallucinations, unconsciousness or another serious medical emergency requires urgent care.
For immediate suicide or self-harm danger, call 911. In the United States, call or text 988 for crisis support.
Want to Compare Medication Options With a Clinician?
A consultation can review the substance involved, physical dependence, previous treatment, current medications, medical history and whether a long-acting antagonist approach is appropriate.
Book a Free DeBinge Consultation →Global Medication-Based Addiction Treatment FAQ
1. Is medication becoming more common in addiction treatment?
Medication is increasingly recognized as a core evidence-based treatment for opioid and alcohol use disorders, although access remains highly uneven globally.
2. What is the most widely used medication treatment for opioid dependence globally?
Opioid agonist treatment, principally methadone and buprenorphine, is the dominant pharmacological treatment.
3. What does WHO recommend for opioid dependence?
WHO identifies opioid agonist maintenance treatment as the preferred option for most patients because of its strong evidence across multiple outcomes.
4. Is methadone simply replacing one addiction with another?
No. Properly delivered methadone treatment is an evidence-based medical treatment for opioid use disorder.
5. How does buprenorphine differ from methadone?
Buprenorphine is a partial opioid agonist, while methadone is a full opioid agonist. Both can reduce withdrawal and craving.
6. What is naltrexone?
Naltrexone is an opioid antagonist used in treatment of opioid use disorder after appropriate opioid withdrawal and also in alcohol use disorder.
7. Why are long-acting medications becoming more popular?
They can reduce frequent dosing decisions and clinic visits and may improve convenience or adherence for some patients.
8. Are weekly buprenorphine injections available?
Yes. The FDA has approved weekly and monthly Brixadi extended-release buprenorphine formulations in the United States.
9. Are naltrexone implants FDA-approved in the United States?
No. The FDA-approved long-acting U.S. naltrexone formulation is an extended-release intramuscular injection.
10. Are naltrexone implants used anywhere in the world?
Sustained-release implants have been studied and used in some settings internationally, but regulatory approval, formulations and availability vary by country.
11. Is an implant more effective than methadone or buprenorphine?
Current evidence does not support claiming that naltrexone implants are universally superior to established opioid agonist treatment.
12. What medications treat alcohol use disorder?
U.S. FDA-approved medications include naltrexone, acamprosate and disulfiram.
13. Does WHO recognize medication treatment for alcohol dependence?
Yes. WHO added naltrexone and acamprosate to its Model List of Essential Medicines for alcohol use disorders in 2023.
14. Is there an approved medication for cocaine addiction?
There is currently no FDA-approved medication specifically for cocaine use disorder.
15. Is there an approved medication for methamphetamine addiction?
There is currently no FDA-approved medication specifically for stimulant use disorder. Behavioral treatment remains central.
16. Is medication treatment available through telehealth?
Some parts of medication treatment can be delivered by telehealth depending on the medication, jurisdiction and applicable regulation.
17. Can primary-care doctors provide addiction medication?
Increasingly yes for several treatments, although rules vary by medication and country.
18. Does medication replace counseling?
Not necessarily. Medication can treat important biological aspects of addiction, while behavioral treatment can address triggers, coping, mental health and lifestyle.
19. Which opioid medication has the strongest evidence?
Methadone and buprenorphine have particularly strong evidence for treatment retention and mortality reduction. Medication choice should still be individualized.
20. How should I choose between medication options?
Work with a qualified clinician to compare the evidence, physical dependence, withdrawal requirements, medical history, treatment goals, accessibility and your preferences.
Modern Addiction Treatment Is Becoming More Medical, More Flexible and More Individualized
The international evidence does not point toward one medication that everyone should receive.
It points toward access to multiple evidence-based options, fewer unnecessary treatment barriers, better continuity and treatment plans designed around the patient.
Long-acting naltrexone can be one part of that landscape for an appropriately selected patient — alongside established alternatives and ongoing behavioral and recovery support.
Evidence Used in This Global Review
UNODC — World Drug Report 2026
Current global data covering treatment coverage, regional differences in treatment and pharmacological interventions.
Explore World Drug Report 2026 →UNODC — Drug Treatment Referral and Interventions
World Drug Report 2026 analysis of how pharmacological, psychosocial and rehabilitation treatment varies by region.
Read UNODC Treatment Analysis →WHO — Opioid Agonist Maintenance Treatment as an Essential Health Service
2025 WHO implementation guidance emphasizing uninterrupted, integrated opioid agonist treatment.
Read WHO Guidance →WHO — Updating Opioid Dependence and Overdose Guidelines
WHO overview of current recommendations and its update of international opioid-dependence treatment guidance.
Read WHO Update →WHO — 2026 Medicine Prequalification Initiative
WHO’s first invitation for prequalification of substance-use treatment medicines, including methadone, buprenorphine and naloxone.
Read WHO 2026 Announcement →EUDA — European Drug Report 2026: Opioid Agonist Treatment
Latest European data on treatment coverage, methadone, buprenorphine and long-acting treatment formulations.
Read European Drug Report →SAMHSA — Treatment Options for Substance Use Disorder
Current U.S. information on medications for opioid and alcohol use disorders.
Read SAMHSA Treatment Options →SAMHSA — 42 CFR Part 8 Treatment Changes
Current U.S. changes involving opioid treatment admission, shared decision-making, methadone take-home flexibility and telehealth.
Review Current U.S. Rules →SAMHSA — MAT Act / Buprenorphine Waiver Elimination
Current information confirming removal of the former federal DATA waiver requirement for buprenorphine prescribing.
Read MAT Act Information →FDA — Current Medications for Opioid Use Disorder
Current FDA list of approved buprenorphine, methadone and naltrexone products for opioid use disorder.
View FDA MOUD Information →FDA — Weekly and Monthly Extended-Release Buprenorphine
FDA announcement regarding Brixadi and expanded long-acting buprenorphine dosing options.
Read FDA Announcement →WHO — Essential Medicines for Alcohol Use Disorders
WHO announcement describing inclusion of naltrexone and acamprosate on the Model List of Essential Medicines.
Read WHO Alcohol Medication Update →NIAAA — Evidence-Based Alcohol Treatment
Current NIH guidance on naltrexone, acamprosate, disulfiram and behavioral treatment.
Read NIAAA Medication Guidance →SAMHSA — 2025 U.S. Treatment Data
Current data showing persistent gaps in receipt of medications for opioid and alcohol use disorders.
Read SAMHSA 2025 Treatment Data →Cochrane 2025 — Sustained-Release Naltrexone
Updated systematic review of injectable and implantable sustained-release naltrexone for opioid dependence.
Read Cochrane Review →NIDA / NIH — Medications for Opioid Use Disorder
Consumer educational video explaining common opioid-treatment medications and overdose reversal.
Watch NIDA Video →Addiction medication policy, licensing and product approval vary between countries. A treatment available in one jurisdiction should not automatically be assumed to have the same regulatory status, formulation or evidence base elsewhere.
Prepared for medical review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry
Review status: Pending clinical approval
Educational information only. Medication decisions require individual clinical assessment. Regulatory status and medication availability vary between countries.